After multiple clinical setbacks and layoff rounds, Mersana accepted an offer in which the bulk of the payouts will only ...

Shares of Mersana Therapeutics catapulted early Thursday after Day One Biopharmaceuticals agreed to buy it for up to $285 ...

Day One Biopharmaceuticals, Inc. is rated a Strong Buy with robust product growth, pipeline expansion & strategic acquisition ...

Mersana Therapeutics' decision earlier this year to go all-in on its antibody-drug conjugate Emi-Le appears to have paid ...

Day One Biopharmaceuticals, Inc. to Acquire Mersana Therapeutics, Inc.Agreement provides for upfront consideration of $25.00 ...

Acquisition expands Day One’s portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le)Emi-Le has ...

BUFFALO, NY – December 4, 2024 – A new editorial was published in Oncotarget’s Volume 15 on November 22, 2024, entitled “B7-H4: A potential therapeutic target in adenoid cystic carcinoma.” Researchers ...

As per the terms of the agreement, Day One will launch a tender offer to acquire all outstanding MRSN shares at a price of ...

Day One Biopharmaceuticals plans to acquire Mersana Therapeutics in a deal worth up to $285 million to expand its cancer drug ...

Day One Biopharmaceuticals has struck a deal to buy fellow biopharmaceutical company Mersana Therapeutics for up to $285 million in cash. Day One on Thursday said it will pay an initial $25 a share, ...

The malignancies of Bartholin's gland, although exceedingly rare, represent a diagnostic and therapeutic challenge for clinicians. Bartholin’s gland carcinoma encompasses several histological subtypes ...